Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

SUSMED

    • Home
    • SUSMED
Others

Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT‑i

Fineline Cube Aug 27, 2026

Shionogi & Co., Ltd. (TYO: 4507) announced that it has terminated its collaboration with SUSMED...

Recent updates

  • China’s NHSA Issues Guiding Opinions Establishing Unified Payment Management for Long‑Term Care Insurance (LTCI)
  • Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%
  • Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First‑Line Gastric Cancer
  • Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT‑i
  • FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s NHSA Issues Guiding Opinions Establishing Unified Payment Management for Long‑Term Care Insurance (LTCI)

Company PIC

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

Company Drug

Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First‑Line Gastric Cancer

Others

Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT‑i

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.